You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
An IASLC survey showed that molecular testing is not performed in line with expert guidelines, which means only a minority of lung cancer patients are benefitting from precision oncology.
The survey results point to the need for greater education among patients so they can better advocate for themselves.
Respondents to GenomeWeb's salary survey reported variations in their salaries that varied by sector.
The survey, conducted by SeraCare Life Sciences and GenomeWeb, asked more than 150 individuals working on clinical NGS about their quality control practices.
Although people have greater access to personalized drugs and tests than ever before, a survey by GenomeWeb and the PMC shows public awareness isn't improving.
More than a third of NGS users plan to purchase a new sequencing system within a year, according to the survey, conducted by GenomeWeb and investment bank William Blair.
According to survey results presented at ASHG, most genetics experts support somatic and germline gene editing, though few favor trait enhancement.
There are signs that doctors may be moving away from experimental precision therapy options in favor of immunotherapy and the chance at longer survival.
In a survey of 132 oncologists, Medscape tracked how they are using next-generation sequencing and what they think of its clinical utility.
There is significant interest in technologies that provide long-range genomic information, but only among a subset of users.
Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.
The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.
Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.
This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.